お気に入りに追加
製品詳細
- ProductSizeAmountActiveMax® Human BCMA μBeads, premium grade (for cells)2.5 mg2.5×10⁷ beadsActiveMax® Human BCMA μBeads, premium grade (for cells)10 mg (2.5 mg×4)1.0×10⁸ beads
Product Show
This product can be directly isolated using conventional column-free magnetic stand (eg. Cat. MB-01/ MB-02/ MB-03/ MB-04). Please note that due to its micron-scale size, it is not compatible with commercially available column-based (M/D/L) magnetic separation systems.
Features
- FDA DMF filed
- Sterility
- Endotoxin content ≤0.002 EU/μg
- Mycoplasma
- Batch-to-batch consistency
Product Description
ActiveMax® Human BCMA μBeads, premium grade (for cells) are uniform, superparamagnetic beads of 5.5 µm in diameter immobilized with Human BCMA protein expressed from human 293 cells (HEK293) and contains AA Met 1 - Ala 54 (Accession # Q02223-1).
ActiveMax® Human BCMA μBeads, premium grade (for cells) are produced under sterile manufacturing conditions (ISO 5), and no animal- or human-derived components are used throughout the production process. It is produced under our rigorous quality control system that includes a comprehensive set of tests including sterility and endotoxin tests.Application
ActiveMax® Human BCMA μBeads, premium grade (for cells) are designed to stimulate in vitro BCMA-specific CAR-T cells or UCAR-T cells, similar to the tumor cell lines that express human BCMA antigen. It can be used as follows:
Evaluating the characteristics of CAR-T cells or UCAR-T cells.
In vitro expansion of BCMA-specific CAR-T cells or UCAR-T cells.
In vitro enrichment of BCMA-specific CAR-T cells or UCAR-T cells.Reconstitution
See Certificate of Analysis (CoA) for detailed instruction.
Storage
This product is stable in storage under the following conditions: -20˚C for 12 months in lyophilized state. -70°C for 3 months under sterile conditions after reconstitution.
Please protect from light and avoid repeated freeze-thaw cycles.Immediate use after reconstitution is highly recommended.
Sterility
Negative
Endotoxin
Less than 0.002 EU per μg by the LAL method / rFC method.
Mycoplasma
Negative
Important Note
This product is for research use only and not intended for therapeutic or in vivo diagnostic use.
Formulation
Lyophilized in PBS with 0.1% HSA，pH 7.4. Trehalose is added as protectant before lyophilization.
ACRO Quality Management System
お客様はこちらも閲覧
データ表示
FACS Data
Assay of human BCMA protein on the μBeads surface by Flow cytometry. The human BCMA conjugated on the μBeads (Cat. No. MBS-C004) surface were fluorescently stained using PE labeled anti-human BCMA antibody and analyzed by flow cytometry.
Protocol
Batch Consistency
Add 100ul of 1:160 PE anti-human BCMA Antibody dilution (0.625 ul stock solution in 99.375 ul FACS buffer) into 5e5 of ActiveMax® human BCMA μBeads, premium grade (for cells) (Cat. No. MBS-C004), negative control beads (ActiveMax® Streptavidin μBeads, premium grade (for cells) (Cat. No. MBS-C009)) as well. PE signals was used to evaluate BCMA beads binding activity.
Stability
Add 100ul of 1:160 PE anti-human BCMA Antibody dilution (0.625 ul stock solution in 99.375 ul FACS buffer) into 5e5 of ActiveMax® human BCMA μBeads, premium grade (for cells) (Cat. No. MBS-C004), Negative control (ActiveMax® Streptavidin μBeads, premium grade (for cells) (Cat. No. MBS-C009)) as well. PE signals was used to evaluate BCMA beads binding activity.
Stimulate BCMA CAR-T Cells -Cytokines
ActiveMax® Human BCMA μBeads, premium grade (for cells) (Cat. No. MBS-C004) can activate BCMA-specific CAR-T cells by detecting the secretion of IFN- γ in vitro.
BCMA CAR-T cells were stimulated with ActiveMax® Human BCMA μBeads (Cat. No. MBS-C004) for 24 h, and cell-free supernatants were harvested for evaluating IFN-γ、TNF-α、IL-4 secretion by flow cytomtry. The results showed that BCMA CAR-T cells released significantly larger amounts of IFN-γ、TNF-α、IL-4 into the supernatants in response to BCMA μBeads (Data is the average of 3 independent experiments, error bars ± SD).
Stimulate BCMA CAR-T Cells -Cytotoxic Molecules
BCMA CAR-T cells were stimulated with ActiveMax® Human BCMA μBeads (Cat. No. MBS-C004) for 24h, and cell-free supernatants were harvested for evaluating Granzyme B secretion by ELISA. The results showed that BCMA CAR-T cells released significantly larger amounts of Granzyme B into the supernatants in response to BCMA μBeads (Data is the average of 3 independent experiments, error bars ± SD).
Stimulate BCMA CAR-T Cells -Activation Marker
BCMA CAR-T cells were stimulated with ActiveMax® Human BCMA μBeads (Cat. No. MBS-C004) for 24h. After demagnetization of the beads, the cells were collected and CD25, CD69, and CD137 were detected by FACS. The results indicated that BCMA CAR-T cells responded to BCMA μBeads, and the expressions of the three markers increased (Data is the average of 3 independent experiments, error bars ± SD).
Stimulate BCMA CAR-T Cells -Exhaustion Marker
BCMA CAR-T cells were stimulated with ActiveMax® Human BCMA μBeads (Cat. No. MBS-C004) for 24h. After demagnetization of the beads, the cells were collected and LAG3, PD-1 were detected by FACS. The results indicated that BCMA CAR-T cells responded to BCMA μBeads, and the expressions of the two markers increased (Data is the average of 3 independent experiments, error bars ± SD).
ユーザーレビュー コメントを投稿
最新の進展
医薬品開発の進捗- 英語名：
B-cell maturation protein
- カテゴリ：
- 市販の医薬品数：
8 詳細
- 治験医薬品数：
145 詳細
- 最新の開発ステージ：
Approved
お問い合わせ
メールアドレス
order.jp@acrobiosystems.com
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
医薬品候補ライセンス
